NASDAQ:MDGL - Madrigal Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$131.97 +1.39 (+1.06 %)
(As of 05/21/2018 01:39 AM ET)
Previous Close$131.97
Today's Range$130.73 - $134.9750
52-Week Range$13.09 - $154.75
Volume154,233 shs
Average Volume183,207 shs
Market Capitalization$1.88 billion
P/E Ratio-51.96
Dividend YieldN/A
Beta1.37

About Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals logoMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MDGL
CUSIP87162T20
Phone484-380-9263

Debt

Debt-to-Equity RatioN/A
Current Ratio29.12
Quick Ratio29.12

Price-To-Earnings

Trailing P/E Ratio-51.96
Forward P/E Ratio-53.21
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$12.43 per share
Price / Book10.62

Profitability

EPS (Most Recent Fiscal Year)($2.54)
Net Income$-31,150,000.00
Net MarginsN/A
Return on Equity-26.52%
Return on Assets-24.88%

Miscellaneous

Employees8
Outstanding Shares14,250,000

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals (NASDAQ:MDGL) released its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.33. View Madrigal Pharmaceuticals' Earnings History.

What price target have analysts set for MDGL?

7 brokers have issued 1 year price targets for Madrigal Pharmaceuticals' stock. Their predictions range from $125.00 to $210.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $164.50 in the next twelve months. View Analyst Ratings for Madrigal Pharmaceuticals.

Who are some of Madrigal Pharmaceuticals' key competitors?

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the folowing people:
  • Dr. Paul A. Friedman, Chairman, Pres & CEO (Age 75)
  • Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 64)
  • Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 66)

Has Madrigal Pharmaceuticals been receiving favorable news coverage?

News articles about MDGL stock have trended somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rock Springs Capital Management LP (2.28%), BlackRock Inc. (2.24%), Victory Capital Management Inc. (1.42%), Citadel Advisors LLC (1.34%), Millennium Management LLC (0.65%) and Northern Trust Corp (0.52%). View Institutional Ownership Trends for Madrigal Pharmaceuticals.

Which major investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC, Rock Springs Capital Management LP, Victory Capital Management Inc., D.A. Davidson & CO. and Caxton Corp. View Insider Buying and Selling for Madrigal Pharmaceuticals.

Which major investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Artal Group S.A., UBS Group AG, Nexthera Capital LP, JPMorgan Chase & Co., Barclays PLC and Eventide Asset Management LLC. View Insider Buying and Selling for Madrigal Pharmaceuticals.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $131.97.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $1.88 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]


MarketBeat Community Rating for Madrigal Pharmaceuticals (MDGL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Madrigal Pharmaceuticals in the last 12 months. Their average twelve-month price target is $164.50, suggesting that the stock has a possible upside of 24.65%. The high price target for MDGL is $210.00 and the low price target for MDGL is $125.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.863.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $164.50$164.50$166.50$63.3333
Price Target Upside: 24.65% upside42.49% upside31.07% upside33.28% upside

Madrigal Pharmaceuticals (NASDAQ:MDGL) Consensus Price Target History

Price Target History for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018CowenReiterated RatingBuyHighView Rating Details
5/8/2018OppenheimerSet Price TargetHold$130.00MediumView Rating Details
3/23/2018Goldman SachsInitiated CoverageBuy$191.00HighView Rating Details
2/9/2018Roth CapitalBoost Price TargetBuy$170.00 ➝ $210.00LowView Rating Details
2/8/2018Evercore ISIReiterated RatingOutperform ➝ Outperform$140.00 ➝ $175.00HighView Rating Details
1/30/2018HC WainwrightBoost Price TargetBuy ➝ Buy$105.00 ➝ $156.00HighView Rating Details
12/6/2017JMP SecuritiesBoost Price TargetOutperform$63.00 ➝ $125.00HighView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings History and Estimates Chart

Earnings by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings Estimates

2018 EPS Consensus Estimate: ($2.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.71)($0.71)($0.71)
Q2 20181($0.46)($0.46)($0.46)
Q3 20181($0.52)($0.52)($0.52)
Q4 20181($0.61)($0.61)($0.61)

Madrigal Pharmaceuticals (NASDAQ MDGL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.7770)($0.45)ViewN/AView Earnings Details
3/13/2018Q4 2017($0.70)($0.67)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.7870)($0.68)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.60)($0.69)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.87)($0.50)ViewN/AView Earnings Details
4/3/2017Q4 2016($1.39)($0.67)ViewN/AView Earnings Details
11/14/2016Q3 2016($1.34)ViewN/AView Earnings Details
7/20/2016Q2 2016($0.70)ViewN/AView Earnings Details
5/10/2016Q1 2016($1.75)ViewN/AView Earnings Details
3/15/2016Q4($0.18)($0.08)ViewN/AView Earnings Details
11/5/2015Q3($0.16)($0.13)ViewN/AView Earnings Details
8/6/2015Q215($0.18)($0.15)ViewListenView Earnings Details
5/7/2015Q115($0.19)($0.19)ViewListenView Earnings Details
3/12/2015Q4($0.19)($0.19)$0.13 millionViewListenView Earnings Details
11/6/2014Q3($0.23)($0.19)$0.13 millionViewListenView Earnings Details
8/6/2014Q2($0.25)($0.24)$480.00 millionViewListenView Earnings Details
5/8/2014Q1($0.28)($0.28)ViewListenView Earnings Details
3/11/2014Q4($0.30)($0.31)$0.37 millionViewListenView Earnings Details
11/4/2013Q313($0.31)($0.33)ViewListenView Earnings Details
8/1/2013Q2 2013($0.30)($0.33)ViewListenView Earnings Details
4/30/2013Q1 2013($9.79)($10.49)ViewN/AView Earnings Details
3/14/2013Q4 2012($9.44)($10.14)ViewN/AView Earnings Details
11/6/2012Q312($0.24)($0.25)$1.60 millionViewN/AView Earnings Details
8/2/2012Q2 2012($9.44)($8.88)ViewN/AView Earnings Details
5/3/2012Q1 2012($8.74)($9.44)ViewN/AView Earnings Details
2/22/2012Q4 2011($9.44)($7.59)ViewN/AView Earnings Details
11/3/2011Q3 2011($9.79)($10.56)ViewN/AView Earnings Details
8/4/2011Q2 2011($6.64)($10.35)ViewN/AView Earnings Details
5/5/2011Q1 2011($9.44)($9.48)ViewN/AView Earnings Details
3/11/2011Q4 2010($5.24)($7.48)ViewN/AView Earnings Details
11/4/2010Q3 2010($7.69)($8.88)ViewN/AView Earnings Details
8/9/2010Q2 2010($8.04)($7.69)ViewN/AView Earnings Details
5/4/2010Q1 2010($7.34)($8.39)ViewN/AView Earnings Details
3/11/2010Q4 2009($9.09)($7.24)ViewN/AView Earnings Details
11/4/2009Q3 2009$61.19$121.82ViewN/AView Earnings Details
8/4/2009Q2 2009($11.89)($8.78)ViewN/AView Earnings Details
5/7/2009Q1 2009($18.88)($23.01)ViewN/AView Earnings Details
3/26/2009Q4 2008($28.32)($26.89)ViewN/AView Earnings Details
11/13/2008Q3 2008($22.38)($27.27)ViewN/AView Earnings Details
8/7/2008Q2 2008($19.93)($23.53)ViewN/AView Earnings Details
5/14/2008Q1 2008($19.23)($18.29)ViewN/AView Earnings Details
3/20/2008Q4 2007($18.18)($16.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Madrigal Pharmaceuticals (NASDAQ:MDGL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 66.40%
Institutional Ownership Percentage: 36.25%
Insider Trading History for Madrigal Pharmaceuticals (NASDAQ:MDGL)
Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2017Richard S LevyDirectorBuy2,000$16.12$32,240.007,200View SEC Filing  
8/22/2017Richard S LevyDirectorBuy3,550$16.12$57,226.003,640View SEC Filing  
8/21/2017Richard S LevyDirectorBuy3,550$15.88$56,374.00900View SEC Filing  
12/14/2015Keith R GollustDirectorSell600,000$0.35$210,000.00401,764View SEC Filing  
12/9/2015Keith R GollustDirectorSell745,892$0.38$283,438.96401,764View SEC Filing  
12/8/2015Bruce KovnerDirectorSell1,523,346$0.37$563,638.023,092,677View SEC Filing  
12/3/2015Bruce KovnerDirectorSell1,430,753$0.43$615,223.793,092,677View SEC Filing  
11/30/2015Bruce KovnerDirectorSell3,078,820$0.48$1,477,833.603,092,677View SEC Filing  
11/24/2015Bruce KovnerDirectorSell1,173,582$0.44$516,376.083,092,677View SEC Filing  
11/20/2015Bruce KovnerDirectorSell1,513,088$0.49$741,413.123,092,677View SEC Filing  
11/17/2015Bruce KovnerDirectorSell1,223,936$0.43$526,292.483,092,677View SEC Filing  
11/12/2015Bruce KovnerDirectorSell5,436,673$0.55$2,990,170.153,092,677View SEC Filing  
11/10/2015Keith R GollustDirectorSell188,322$0.55$103,577.10401,764View SEC Filing  
4/6/2015Robert N WilsonDirectorBuy50,000$1.75$87,500.00View SEC Filing  
9/30/2014Bruce KovnerDirectorBuy300,000$3.08$924,000.00View SEC Filing  
4/11/2014Bruce KovnerDirectorBuy1,250,000$4.01$5,012,500.003,048,666View SEC Filing  
11/13/2013Bruce KovnerDirectorBuy5,000,000$3.75$18,750,000.006,130,330View SEC Filing  
11/13/2013Safi BahcallCEOBuy20,000$3.75$75,000.002,053,135View SEC Filing  
6/28/2013Safi R BahcallCEOBuy10,000$5.03$50,300.00View SEC Filing  
6/27/2013Bruce KovnerDirectorBuy150,000$4.71$706,500.00View SEC Filing  
6/26/2013Bruce KovnerDirectorBuy500,000$4.53$2,265,000.00View SEC Filing  
6/21/2013Bruce KovnerDirectorBuy250,000$4.39$1,097,500.00View SEC Filing  
6/21/2013Safi R BahcallCEOBuy20,000$4.12$82,400.00View SEC Filing  
6/18/2013Bruce KovnerDirectorBuy200,000$4.00$800,000.00View SEC Filing  
6/14/2013Safi R BahcallCEOBuy10,000$4.06$40,600.00View SEC Filing  
6/6/2013Bruce KovnerDirectorBuy2,000,000$4.64$9,280,000.00View SEC Filing  
6/6/2013Safi R BahcallCEOBuy10,000$4.04$40,400.00View SEC Filing  
6/5/2013Vojo VukovicSVPBuy10,000$4.58$45,800.00View SEC Filing  
6/4/2013Robert N WilsonDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/14/2012Bruce KovnerDirectorBuy37,700$6.91$260,507.00View SEC Filing  
11/12/2012Safi R BahcallCEOBuy10,000$7.12$71,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Madrigal Pharmaceuticals (NASDAQ MDGL) News Headlines

Source:
DateHeadline
Madrigal Pharmaceuticals (MDGL) Receives Consensus Rating of "Buy" from AnalystsMadrigal Pharmaceuticals (MDGL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 19 at 1:35 AM
Madrigal Pharmaceuticals (MDGL) Shares March Higher, Can It Continue?Madrigal Pharmaceuticals (MDGL) Shares March Higher, Can It Continue?
www.zacks.com - May 16 at 5:11 PM
 Analysts Expect Madrigal Pharmaceuticals (MDGL) Will Post Earnings of -$0.59 Per Share Analysts Expect Madrigal Pharmaceuticals (MDGL) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - May 11 at 1:20 PM
Zacks Investment Research Upgrades Madrigal Pharmaceuticals (MDGL) to "Buy"Zacks Investment Research Upgrades Madrigal Pharmaceuticals (MDGL) to "Buy"
www.americanbankingnews.com - May 11 at 12:49 PM
Analysts Issue Forecasts for Madrigal Pharmaceuticals Q2 2018 Earnings (MDGL)Analysts Issue Forecasts for Madrigal Pharmaceuticals' Q2 2018 Earnings (MDGL)
www.americanbankingnews.com - May 11 at 8:35 AM
Madrigal Pharmaceuticals (MDGL) Announces Quarterly  Earnings ResultsMadrigal Pharmaceuticals (MDGL) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 9:53 PM
Madrigal Pharmaceuticals (MDGL) "Buy" Rating Reaffirmed at CowenMadrigal Pharmaceuticals' (MDGL) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - May 10 at 9:37 PM
Madrigal Pharmaceuticals (MDGL) Given a $130.00 Price Target at OppenheimerMadrigal Pharmaceuticals (MDGL) Given a $130.00 Price Target at Oppenheimer
www.americanbankingnews.com - May 9 at 12:08 PM
Madrigal: 1Q Earnings SnapshotMadrigal: 1Q Earnings Snapshot
www.cnbc.com - May 8 at 5:11 PM
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical AchievementsMadrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
finance.yahoo.com - May 8 at 8:44 AM
-$0.75 Earnings Per Share Expected for Madrigal Pharmaceuticals (MDGL) This Quarter-$0.75 Earnings Per Share Expected for Madrigal Pharmaceuticals (MDGL) This Quarter
www.americanbankingnews.com - April 24 at 3:20 AM
Madrigal Pharmaceuticals (MDGL) Receives Consensus Rating of "Buy" from BrokeragesMadrigal Pharmaceuticals (MDGL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 24 at 1:30 AM
Oppenheimer Weighs in on Madrigal Pharmaceuticals Q1 2018 Earnings (MDGL)Oppenheimer Weighs in on Madrigal Pharmaceuticals' Q1 2018 Earnings (MDGL)
www.americanbankingnews.com - April 19 at 6:50 AM
UPDATE: Oppenheimer Starts Madrigal Pharmaceuticals (MDGL) at PerformUPDATE: Oppenheimer Starts Madrigal Pharmaceuticals (MDGL) at Perform
www.streetinsider.com - April 18 at 5:22 PM
Madrigal Pharmaceuticals (MDGL) Now Covered by OppenheimerMadrigal Pharmaceuticals (MDGL) Now Covered by Oppenheimer
www.americanbankingnews.com - April 16 at 6:30 PM
Madrigal Pharmaceuticals Inc (MDGL) Short Interest Up 50.0% in MarchMadrigal Pharmaceuticals Inc (MDGL) Short Interest Up 50.0% in March
www.americanbankingnews.com - April 14 at 2:27 AM
Cowen Reaffirms "Buy" Rating for Madrigal Pharmaceuticals (MDGL)Cowen Reaffirms "Buy" Rating for Madrigal Pharmaceuticals (MDGL)
www.americanbankingnews.com - April 13 at 1:35 PM
Active-Investors: Wired News - BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC PatientsActive-Investors: Wired News - BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC Patients
www.finanznachrichten.de - April 12 at 9:21 AM
Wired News – BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC PatientsWired News – BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC Patients
finance.yahoo.com - April 12 at 9:21 AM
Blog Exposure - Therapix Reported Positive Top-line Results of Phase-IIa Study for Tourette Syndrome TreatmentBlog Exposure - Therapix Reported Positive Top-line Results of Phase-IIa Study for Tourette Syndrome Treatment
finance.yahoo.com - April 11 at 9:07 AM
Madrigal Pharmaceuticals Inc (MDGL) Expected to Announce Earnings of -$0.77 Per ShareMadrigal Pharmaceuticals Inc (MDGL) Expected to Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 7 at 5:21 AM
Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 4 at 8:47 AM
Madrigal Pharmaceuticals (MDGL) Raised to "Buy" at ValuEngineMadrigal Pharmaceuticals (MDGL) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM
Madrigal Pharmaceuticals Inc (MDGL) Receives Consensus Rating of "Buy" from AnalystsMadrigal Pharmaceuticals Inc (MDGL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 30 at 1:32 AM
Zacks Investment Research Upgrades Madrigal Pharmaceuticals (MDGL) to BuyZacks Investment Research Upgrades Madrigal Pharmaceuticals (MDGL) to Buy
www.americanbankingnews.com - March 29 at 6:54 PM
Madrigal Pharmaceuticals (MDGL) PT Raised to $156.00Madrigal Pharmaceuticals (MDGL) PT Raised to $156.00
www.americanbankingnews.com - March 26 at 3:13 PM
Madrigal Pharmaceuticals (MDGL) Coverage Initiated at Goldman SachsMadrigal Pharmaceuticals (MDGL) Coverage Initiated at Goldman Sachs
www.americanbankingnews.com - March 23 at 6:50 PM
Goldman Sachs: Madrigal Pharma Has Blockbuster Potential In Liver, Cholesterol TreatmentsGoldman Sachs: Madrigal Pharma Has Blockbuster Potential In Liver, Cholesterol Treatments
finance.yahoo.com - March 23 at 5:15 PM
Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session - NasdaqMadrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session - Nasdaq
www.nasdaq.com - March 21 at 9:37 AM
Madrigal Pharmaceuticals (MDGL) & Raptor Pharmaceutical (RPTP) Critical ComparisonMadrigal Pharmaceuticals (MDGL) & Raptor Pharmaceutical (RPTP) Critical Comparison
www.americanbankingnews.com - March 18 at 11:30 AM
Roth Capital Reiterates Buy on Madrigal Pharma (MDGL) Following 4Q and Clinical Confusion - StreetInsider.comRoth Capital Reiterates Buy on Madrigal Pharma (MDGL) Following 4Q and Clinical Confusion - StreetInsider.com
www.streetinsider.com - March 18 at 8:42 AM
Madrigal Pharmaceuticals (MDGL) Downgraded to "Buy" at BidaskClubMadrigal Pharmaceuticals (MDGL) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 16 at 11:00 PM
Madrigal Pharmaceuticals (MDGL) Presents At 38th Annual Cowen and Company Healthcare Conference - SlideshowMadrigal Pharmaceuticals (MDGL) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 5:41 PM
Madrigal Pharmaceuticals (MDGL) Releases  Earnings ResultsMadrigal Pharmaceuticals (MDGL) Releases Earnings Results
www.americanbankingnews.com - March 14 at 9:43 AM
BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67
www.reuters.com - March 13 at 6:57 PM
Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196
finance.yahoo.com - March 13 at 8:55 AM
Sectoral Asset Management Inc Takes $3.38 Million Position in Madrigal Pharmaceuticals Inc (MDGL)Sectoral Asset Management Inc Takes $3.38 Million Position in Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - March 6 at 2:10 PM
Madrigal Pharmaceuticals Inc (MDGL) Given Consensus Rating of "Buy" by BrokeragesMadrigal Pharmaceuticals Inc (MDGL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 5 at 1:30 AM
-$0.68 Earnings Per Share Expected for Madrigal Pharmaceuticals Inc (MDGL) This Quarter-$0.68 Earnings Per Share Expected for Madrigal Pharmaceuticals Inc (MDGL) This Quarter
www.americanbankingnews.com - March 4 at 1:08 AM
Bogle Investment Management L P DE Buys New Stake in Madrigal Pharmaceuticals Inc (MDGL)Bogle Investment Management L P DE Buys New Stake in Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - March 3 at 4:52 AM
Hudson Bay Capital Management LP Takes $2.75 Million Position in Madrigal Pharmaceuticals Inc (MDGL)Hudson Bay Capital Management LP Takes $2.75 Million Position in Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - March 1 at 12:03 PM
Madrigal Pharmaceuticals Inc (MDGL) Holdings Boosted by Ascend Capital LLCMadrigal Pharmaceuticals Inc (MDGL) Holdings Boosted by Ascend Capital LLC
www.americanbankingnews.com - March 1 at 4:41 AM
Madrigal Pharmaceuticals (MDGL) Coverage Initiated by Analysts at CowenMadrigal Pharmaceuticals (MDGL) Coverage Initiated by Analysts at Cowen
www.americanbankingnews.com - March 1 at 12:30 AM
EAM Investors LLC Acquires Shares of 57,960 Madrigal Pharmaceuticals Inc (MDGL)EAM Investors LLC Acquires Shares of 57,960 Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - February 27 at 3:00 PM
Madrigal (MDGL) Q4 Earnings: Whats in Store for the Stock?Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
www.zacks.com - February 26 at 5:26 PM
3 Top Biotech Stocks to Buy in February3 Top Biotech Stocks to Buy in February
finance.yahoo.com - February 26 at 8:41 AM
Zacks: Brokerages Expect Madrigal Pharmaceuticals Inc (MDGL) Will Announce Earnings of -$0.68 Per ShareZacks: Brokerages Expect Madrigal Pharmaceuticals Inc (MDGL) Will Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - February 15 at 1:24 PM
Madrigal Pharmaceuticals (MDGL) PT Raised to $210.00Madrigal Pharmaceuticals (MDGL) PT Raised to $210.00
www.americanbankingnews.com - February 9 at 10:36 PM
Here’s What’s Moving Teva Pharmaceutical Industries And Madrigal PharmaceuticalsHere’s What’s Moving Teva Pharmaceutical Industries And Madrigal Pharmaceuticals
finance.yahoo.com - February 9 at 9:39 AM
Madrigal Pharmaceuticals (MDGL) Outperform Rating Reiterated at Evercore ISIMadrigal Pharmaceuticals' (MDGL) Outperform Rating Reiterated at Evercore ISI
www.americanbankingnews.com - February 8 at 11:18 AM

SEC Filings

Madrigal Pharmaceuticals (NASDAQ:MDGL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Madrigal Pharmaceuticals (NASDAQ:MDGL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Madrigal Pharmaceuticals (NASDAQ MDGL) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.